Mark Fendrick, MD, Discusses Value-Based Insurance Design
Dr. Mark Fendrick, MD, Professor of Medicine and Health Management and Policy, Schools of Medicine and Public Health, University of Michigan, Co-Editor-in-Chief, The American Journal of Managed Care, says that there are levers organizations and stakeholders can pull to achieve the goal of improving quality and value in cancer care. Dr. Fendrick discusses the importance of combining the supply side, or how you pay doctors, and the demand side of value, or consumer engagement. Dr. Fendrick also says that the goal of improved health and cost containment can be achieved when the two sides are combined.
This video was taken on November 16 at AJMC's Translating Evidence-Based Research Into Value-Based Decisions in Oncology.
No state-run exchange, no subsidy for health coverage. That’s what a federal judge in Oklahoma ruled yesterday, marking the second such ruling against a key component of the Affordable Care Act and setting up a potential return trip to the US Supreme Court to decide the fate of a key piece of the law.
Results from 2 phase 3 trials showed better response rates, progression-free survival, and overall survival when a BRAF inhibitor was combined with a MEK inhibitor, compared with a BRAF inhibitor alone.
The most recent Medicare Advantage and Part D program audits revealed that oversight of formulary administration is an area that health plans continue to struggle with, Sarah J. Lorance, vice president of Medicare Compliance at WellPoint, said at America’s Health Insurance Plans’ National Conference on Medicare and Medicaid and Dual Eligibles Summit in Washington, DC.